NCT01473251View on ClinicalTrials.gov

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Exudative Macular DegenerationDiabetic Macular Edema
Interventions
DRUG

Avastin

1.25 mg monthly for 4 months

DRUG

Avastin

1.25 mg monthly for 4 months

DRUG

Lucentis

0.5 mg monthly for 4 months

Trial Locations (1)

49525

Vitreo-Retinal Associates, Grand Rapids

All Listed Sponsors
collaborator

Van Andel Research Institute

OTHER

lead

Vitreo-Retinal Associates, Michigan

OTHER

NCT01473251 - Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration | Biotech Hunter | Biotech Hunter